Informa PLC (LON:INF) Investors: Berenberg Reaffirms “Buy” Rating, Sees GBX 800.00/Share; Sophiris Bio (SPHS)’s Sentiment Is 2.8

March 8, 2018 - By Jerrie Dane

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $64.74 million. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

In an analyst report sent to clients and investors on Thursday, 8 March, Informa PLC (LON:INF) stock “Buy” was reiterated at Berenberg. They currently have a GBX 800.00 TP on the stock. Berenberg’s TP suggests a potential upside of 11.97% from the company’s last stock price.

It closed at $2.15 lastly. It is down 192.94% since March 8, 2017 and is uptrending. It has outperformed by 176.24% the S&P500.

Sabby Management Llc holds 0.05% of its portfolio in Sophiris Bio, Inc. for 333,641 shares. Palo Alto Investors Llc owns 247,000 shares or 0.02% of their US portfolio. Moreover, B & T Capital Management Dba Alpha Capital Management has 0.01% invested in the company for 10,128 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of Montreal Can, a Ontario – Canada-based fund reported 210 shares.

Analysts await Sophiris Bio, Inc. (NASDAQ:SPHS) to report earnings on March, 26. They expect $-0.11 earnings per share, down 57.14% or $0.04 from last year’s $-0.07 per share. After $-0.11 actual earnings per share reported by Sophiris Bio, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 1.58 in Q3 2017. Its up 0.35, from 1.23 in 2017Q2. It increased, as 1 investors sold Informa plc shares while 12 reduced holdings. 8 funds opened positions while 8 raised stakes. 3.16 million shares or 2.59% more from 3.08 million shares in 2017Q2 were reported. Sii Investments Inc Wi invested in 0.02% or 29,370 shares. Landscape Cap Mngmt Limited Liability Corporation owns 10,902 shares. Kayne Anderson L P, a California-based fund reported 17,000 shares. Morgan Stanley stated it has 596,697 shares. Boothbay Fund Mngmt Ltd stated it has 10,000 shares. Invesco, Georgia-based fund reported 128,848 shares. Citigroup Inc stated it has 0% of its portfolio in Informa plc (LON:INF). Guggenheim Capital Ltd Liability reported 558,836 shares stake. Cambridge Investment Rech Advsrs Inc holds 0.01% of its portfolio in Informa plc (LON:INF) for 35,566 shares. Ashford Capital Mngmt has 0.67% invested in Informa plc (LON:INF) for 306,126 shares. Royal Retail Bank Of Canada has invested 0% in Informa plc (LON:INF). Shaker Financial Svcs Limited Liability Company holds 0.2% or 28,612 shares in its portfolio. Cornerstone Advsrs invested in 0.24% or 152,162 shares. Parametric Assoc Ltd reported 59,389 shares. Comml Bank Of America De has 0% invested in Informa plc (LON:INF).

Informa PLC, together with its subsidiaries, operates in business intelligence, academic publishing, and knowledge and events businesses worldwide. The company has market cap of 5.88 billion GBP. It operates in five divisions: Academic Publishing, Business Intelligence, Global Exhibitions, Knowledge & Networking, and Penton Information Services. It has a 18.92 P/E ratio. The Academic Publishing segment publishes books and journals in print and electronic formats primarily for academic and research users in the areas of humanities and social sciences, science, technology, and medicine.